SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer
Abstract
New treatment strategies such as immune checkpoint inhibitors and oncolytic viruses are opening new possibilities in cancer therapy. Preliminary results in melanoma and other tumors showed that the combination of talimogene laherparepvec with an anti-PD-1/PD-L1 or anti-CTLA4 has greater efficacy than either therapy alone, without additional safety concerns beyond those expected for each agent. The presence of residual cancer after neoadjuvant chemotherapy in early breast cancer patients is an unmet medical need. SOLTI-1503 PROMETEO is a window of opportunity trial, which evaluates the combination of talimogene laherparepvec in combination with atezolizumab in women with operable HER2-negative breast cancer who present residual disease after neoadjuvant chemotherapy. The primary end point is the rate of residual cancer burden 0/1.
Clinical Trial Registration: NCT03802604
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann. Oncol. 17(3), 409–414 (2006).
- 2. Neoadjuvant management of early breast cancer: a clinical and investigational position statement. Oncologist 24(5), 603–611 (2019).
- 3. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938), 164–172 (2014). • Metanalysis shows the poor prognosis of residual disease following neoadjuvant chemotherapy in breast cancer patients.
- 4. . State of the art in neoadjuvant therapy of breast cancer. EJC 11(Suppl. 2), 284–285 (2013).
- 5. Research issues affecting preoperative systemic therapy for operable breast cancer. J. Clin. Oncol. 26(5), 806–813 (2008).
- 6. . Pathological complete response and accelerated drug approval in early breast cancer. N. Engl. J. Med. 366(26), 2438–2441 (2012).
- 7. . Neoadjuvant therapy in breast cancer as a basis for drug approval. JAMA Oncol. 1(7), 875–876 (2015).
- 8. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, Phase II trial. Lancet Oncol. 13(1), 25–32 (2012).
- 9. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30(15), 1796–1804 (2012).
- 10. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci. Transl. Med. 9(397), eaan0026 (2017).
- 11. Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: Phase III GeparQuattro study. J. Clin. Oncol. 28(12), 2015–2023 (2010).
- 12. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N. Engl. J. Med. 366(4), 310–320 (2012).
- 13. . Neoadjuvant dose-dense and dose-intensified chemotherapy in breast cancer-review of the literature. Breast Care 11(1), 13–20 (2016).
- 14. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N. Engl. J. Med. 376(22), 2147–2159 (2017).
- 15. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380(7), 617–628 (2019).
- 16. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 31(7), 860–867 (2013).
- 17. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19(1), 40–50 (2018).
- 18. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 18(1), 52–62 (2017).
- 19. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 32(27), 2959–2966 (2014).
- 20. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann. Oncol. 29(1), 170–177 (2018).
- 21. . Immunotherapy in breast cancer: an introduction. Breast 37, 196–199 (2017).
- 22. . Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. J. Immunother. Cancer 7(1), 90 (2019).
- 23. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol. 25(8), 1536–1543 (2014).
- 24. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, Phase Ib-II trial. Lancet Oncol. 20(3), 371–382 (2019).
- 25. . Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol. Immunol. 67(2 Pt A), 4–17 (2015).
- 26. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563–567 (2014).
- 27. . The future of cancer treatment: will it include immunotherapy? Cancer Cell 22(1), 7–8 (2012).
- 28. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 21(1), 44–59 (2019).
- 29. LBA8_PR KEYNOTE-522: phase III study of pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (pbo)+ chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Ann. Oncol. 382(9), 810–821 (2020).
- 30. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann. Oncol. 25(3), 611–618 (2014).
- 31. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 17, 124 (2015).
- 32. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin. Cancer Res. 22(6), 1499–1509 (2016).
- 33. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann. Oncol. 30(2), 236–242 (2018).
- 34. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy. Breast Cancer Res. Treat. 179(1), 11–23 (2019).
- 35. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12(22), 6737–6747 (2006).
- 36. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27(34), 5763 (2009).
- 37. One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL). J. Clin. Oncol. 37(Suppl. 15), 9520–9520 (2019).
- 38. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma. J. Immunother. Cancer 7(1), 145 (2019). •• First randomized Phase III data demonstrate superior efficacy achieved by talimogene laherparepvec in unresectable stage III–IV melanoma.
- 39. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33(25), 2780–2788 (2015).
- 40. Primary analysis of a Phase Ib multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. Clinical Oncology. 32(Suppl. 15),9029–9029 (2014).
- 41. Randomized, open-label Phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36(17), 1658 (2018).
- 42. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170(6), 1109–1119. e1110 (2017).
- 43. Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck.Clinical Oncology. 36(Suppl. 15), 6036–6036 (2018).
- 44. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a Phase II clinical trial. JAMA Oncol. 6(3), 402–408 (2020).
- 45. . Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca). (Journal of Clinical Oncology. 30(Suppl. 15), e14546–e14546 (2012).
- 46. Abstract CT040: a Phase I trial of talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer. Cancer Res. 79(Suppl. 13), CT040–CT040 (2019).
- 47. . Cancer-fighting viruses win approval. Nature 526(7575), 622 (2015).
- 48. . Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy 11(8), 705–723 (2019). • Rationale for use of talimogene laherparepvec in combination with immune checkpoint inhibitors.
- 49. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 5(1), 74–82 (2018). • Long-term outcomes from Phase I clinical trial of atezolizumab monotherapy in triple negative breast cancer.
- 50. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a Phase Ib clinical trial atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast canceratezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer. JAMA Oncol. 5(3), 334–342 (2019).
- 51. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379(22), 2108–2121 (2018). •• First randomized Phase III data demonstrate superior efficacy achieved by combining atezolizumab with nab-paclitaxel in first-line for triple-negative breast cancer.
- 52. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382(9), 810–821 (2020). •• First randomized Phase III data demonstrate superior efficacy achieved by pembrolizumab in combination with neoadjuvant chemotherapy in triple negative breast cancer.
- 53. A randomised Phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol. 30(8), 1279–1288 (2019).
- 54. Abstract GS3-04: pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. 80(Suppl. 4), (2020).
- 55. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372(26), 2521–2532 (2015).
- 56. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25(28), 4414–4422 (2007).
- 57. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J. Immunother. Cancer 6(1), 63 (2018).
- 58. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27(8), 1160 (2009).
- 59. . Fundamentals of biostatistics. Nelson Education (2015). https://onlinelibrary.wiley.com/doi/abs/10.1002/bimj.4710350205